Please login to the form below

Not currently logged in
Email:
Password:

Cuttsy+Cuttsy retains IPA gold standard in CPD

Staff investment recognised by the Institute of Practitioners in Advertising

Cuttsy + Cuttsy gold IPA CPD

Cuttsy+Cuttsy has been awarded the gold standard in continuous professional development (CPD) by the Institute of Practitioners in Advertising (IPA).

It’s the second year in a row the Cambridge, UK-based healthcare communications agency has picked up the award, which recognises the best professional development offered by IPA members.

More than 300 agencies are part of the IPA and only 36 achieve the gold standard after submitting their CPD programmes for evaluation.

Mathew Cutts, one of Cuttsy+Cuttsy’s founding directors, said: “I am delighted we have received gold for the second year. It may be a cliché that ‘an agency is only as good as its people’, but it’s true.

“At C+C, the enjoyment of watching people grow, learn and develop is as much of a thrill as developing an amazing piece of creative work. This is why, at the heart of our business, we foster a culture of professional development.”

Article by
Dominic Tyer

3rd May 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics